Glycotest
Merion Station, US · Delaware corporation · 2 known investors
Glycotest develops diagnostic tests for the early detection of liver disease and liver cancer. The company operates in the biomedical diagnostics field within the healthcare industry.
Founders & leadership
CS
Charles SwindellExecutive
Board
II
JJ
Jenny JiangBoard director
Investors · 2
Reported raises · per SEC filings
Form D private placements$3.2M disclosed across 1 round · 2026
▶$3.2MraisedJul 2026 · 3 investors · Other Health CareRule 506(b)
▶$3.2MraisedJul 2026 · 3 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Charles SwindellExecutive Officer, Director
- Ilian IlievDirector
- Ed HooperDirector
- Jenny JiangDirector
- Offering amount
- $6.8M
- Amount sold
- $3.2M
- Sales commissions
- $77.4K
- Placement agents
- EMV Capital Partners
- First sale
- Jun 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
This investment group looks poised to re-rate - Investors' Chronicleinvestorschronicle.co.uk · Jul 2026Frequently asked questions
- What does Glycotest do?
- Glycotest develops diagnostic tests for the early detection of liver disease and liver cancer. The company operates in the biomedical diagnostics field within the healthcare industry.
- Who are Glycotest's investors?
- Glycotest's investors include Fosun Pharma, EMV Capital.
- How much funding has Glycotest raised?
- Glycotest has disclosed $3.2M raised across 1 round.
- Where is Glycotest headquartered?
- Glycotest is headquartered in Merion Station, US.